SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-071400
Filing Date
2023-03-15
Accepted
2023-03-15 16:38:53
Documents
15
Period of Report
2023-03-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d405925d8k.htm   iXBRL 8-K 29589
2 EX-1.1 d405925dex11.htm EX-1.1 185210
3 EX-5.1 d405925dex51.htm EX-5.1 11063
7 GRAPHIC g405925g0314221044227.jpg GRAPHIC 4680
  Complete submission text file 0001193125-23-071400.txt   412874

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA prld-20230315.xsd EX-101.SCH 2845
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE prld-20230315_lab.xml EX-101.LAB 17979
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE prld-20230315_pre.xml EX-101.PRE 11255
9 EXTRACTED XBRL INSTANCE DOCUMENT d405925d8k_htm.xml XML 3399
Mailing Address 200 POWDER MILL ROAD WILMINGTON DE 19803
Business Address 200 POWDER MILL ROAD WILMINGTON DE 19803 (302) 547-3768
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

IRS No.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39527 | Film No.: 23735793
SIC: 2834 Pharmaceutical Preparations